Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
James F DonohueEdward KerwinSanjay SethiBrett HaumannSrikanth PendyalaLorna DeanChris N BarnesEdmund J MoranGlenn D CraterPublished in: Respiratory research (2019)
NCT02518139 ; Registered 5 August 2015.